Methods applied in cost-effectiveness models for treatment strategies in type 2 diabetes mellitus and their use in Health Technology Assessments: a systematic review of the literature from 2008 to 2013

References

• Ahmed KA, Muniandy S, Ismail IS. Type 2 diabetes and vascular complications: a pathophysiologic view. Biomed Res 2010;21:147-55
   Web of Science ®Google Scholar
• International Diabetes Federation. IDF Diabetes Atlas, 5th edn. Brussels, Belgium. 2012. Available at: http://www.idf.org/diabetesatlas
   Google Scholar
• Zhang P, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:293-301
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Chronic Conditions. Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (update). Royal College of Physicians, 2008
   Google Scholar
• Tarride J-E, et al. A review of methods used in long-term cost-effectiveness models of diabetes mellitus treatment. Pharmacoeconomics 2010;28:255-77
   PubMed Web of Science ®Google Scholar
• Yi Y, Philips Z, Bergman G, Burslem K. Economic models in type 2 diabetes. Curr Med Res Opin 2010;26:2105-18
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Consensus Panel. Guidelines for computer modeling of diabetes and its complications. Diabetes Care 2004;27:2262-5
   PubMed Web of Science ®Google Scholar
• Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices – overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force – 1. Value Health ;15:796-803
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79
   PubMed Web of Science ®Google Scholar
• Thurecht L, Brown L, Yap M. Economic modelling of the prevention of type 2 diabetes in Australia – the diabetes model. Int J Microsimulation 2011;4:71-80
   Google Scholar
• Díaz de León-Castañeda C, et al. Cost-effectiveness study of oral hypoglycemic agents in the treatment of outpatients with type 2 diabetes attending a public primary care clinic in Mexico City. Clin Outcomes Res 2012;4:57-65
   PubMedGoogle Scholar
• Hayes AJ, Clarke PM, Voysey M, Keech A. Simulation of quality-adjusted survival in chronic diseases: an application in type 2 diabetes. Med Decis Mak 2011;31:559-70
   PubMed Web of Science ®Google Scholar
• Gillett M, et al. Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis. BMJ 2010;341:c4093
   PubMed Web of Science ®Google Scholar
• Gaede P, et al. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study. Diabetes Care 2008;31:1510-15
   PubMed Web of Science ®Google Scholar
• McEwan P, Evans M, Bergenheim K. A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes. Diabetes Obes Metab 2010;12:623-30
   PubMed Web of Science ®Google Scholar
• McEwan P, Evans M, Kan H, Bergenheim K. Understanding the inter-relationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model. Diabetes Obes Metab 2010;12:431-6
   PubMed Web of Science ®Google Scholar
• McEwan P, Peters JR, Bergenheim K, Currie CJ. Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost–utility model (DiabForecaster). Curr Med Res Opin 2006;22:121-9
   PubMed Web of Science ®Google Scholar
• Lim K. Cost-effectiveness analysis of glimepiride or pioglitazone in combination with metformin in type-II diabetic patients in Korea. Value Health 2010;13:A528
   Google Scholar
• Menzin J, Duczakowski C, Friedman M, et al. An economic model of the effects of quick release bromocriptine mesylate versus alternative oral antidiabetic drugs on hospitalizations and costs. Value Health 2011;14:A97
   Google Scholar
• Van Der Heijden AA, et al. Modelling integrated care for diabetes based on observational data: the MICADO model. Diabetologia 2011;54:S134
   Google Scholar
• Jacob R, Thomson P, Ward K, et al. Cost-effective analysis of U-500 compared with U-100 insulin among obese patients with type 2 diabetes with suboptimal glucose control: retrospective observational study of routine clinical care. Diabet Med 2012;29:30-177
   Google Scholar
• Ikeda S, Kobayashi M. Cost-effectiveness anaysis of glycemic control with pioglitazone hydrochloride for Japanese patients with type II diabetes. Value Health 2002;5:545
   Web of Science ®Google Scholar
• Walczak J, et al. The cost–utility and budget impact analysis of sitagliptin (januvia®) in type 2 diabetes in Poland. Value Health 2008;11:A500
   Google Scholar
• Ward A, Kongnakorn T, Moller J, et al. Simulation of long-term costs of complications in type II diabetes in the United States. Value Health 2007;10:A266
   Google Scholar
• Brun-Strang C, et al. Modeling the impact of a new oral anti-diabetic treatment on diabetes complication costs in France. Value Health 2001;4:504
   Google Scholar
• Stynes G, et al. The cost-effectiveness of pioglitazone in combination with metformin in the treatment of type 2 diabetes mellitus in Scotland. Value Health 2004;7:737-8
   Web of Science ®Google Scholar
• Hisashige A, Katayama T, Mikasa H. Costs and effectiveness of intensive insulin therapy for type 2 diabetes. Value Health 2001;4:114
   Google Scholar
• Stephens J, Botteman M, Ramsdell J, et al. A cost-of-treatment model for type 2 diabetes. Value Health 1999;2:198-9
   Google Scholar
• Fon F, Celaya J, Ayala C, et al. A pharmacoeconomic evaluation for diabetes type 2 (DM2) patients with inhibitors of dipeptidyl peptidase-4 (DPP-4) and thiazolidinediones (TZD) as add-on therapy. Value Health 2007;10:A254
   Google Scholar
• Carlos F, Lemus A. Economic evaluation of glimepiride and glimepiride/metformin for type-2 diabetes mellitus in Mexico. Value Health 2011;14:A95
   Google Scholar
• Tilden D, Mariz S, Diamantopoulos A, O’Bryan-Tear G. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type-2 diabetes mellitus in the UK. Value Health 2005;8:A164
   Google Scholar
• Van der Steen A, Verheggen B, Heeg B, Van Hout B. Dealing with competing causes of death, illness and costs: the disease elimination life table analysis (DELTA) model. Value Health 2007;10:A454
   Google Scholar
• Nagy B, et al. development of a health economic model to compare the prevention, treatment and management strategies of type 2 diabetes. Value Health 2011;14:A486-7
   Google Scholar
• Ridderstrale M, Ericsson A, Jensen M. Short-term cost-effectiveness of insulin detemir versus NPH insulin in insulin-naive subjects with type 2 diabetes in Sweden. Value Health 2011;14:A480
   Google Scholar
• Willis M, Neslusan C, He J, Worbes-Cerezo M. The economic impact of weight loss in patients newly diagnosed with type 2 diabetes mellitus (T2DM) and younger than fifty in Sweden. Value Health 2011;14:A479
   Google Scholar
• Scottish Medicines Consortium. Metformin prolonged release tablets 500mg, 750mg, 1,000mg (Glucophage SR), No. (148/04), Merck Serono Ltd, 4 September 2009
   Google Scholar
• National Institute for Health and Care Excellence (NICE). The clinical effectiveness and cost effectiveness of rosiglitazone for type 2 diabetes mellitus (TA9 rosiglitazone). 2000
   Google Scholar
• National Institute for Health and Care Excellence. Diabetes (type 1 and 2) – inhaled insulin (withdrawn) (TA113). Inhaled insulin for the treatment of diabetes (types 1 and 2). 2006
   Google Scholar
• Clarke PM, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004;47:1747-59
   PubMed Web of Science ®Google Scholar
• Kannel WB, et al. Profile for estimating risk of heart failure. Arch Intern Med 1999;159:1197-204
   PubMed Web of Science ®Google Scholar
• Murabito JM, D’Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation 1997;96:44-9
   PubMed Web of Science ®Google Scholar
• Wilson PW, Evans JC. Coronary artery disease prediction. Am J Hypertens 1993;6:309-13S
   Google Scholar
• Flegal K, Troiano R. Changes in the distribution of body mass index of adults and children in the US population. Int J Obes 2000;24:807-18
   PubMed Web of Science ®Google Scholar
• Meigs JB, Nathan DM, Cupples LA, et al. Tracking of glycated hemoglobin in the original cohort of the Framingham Heart Study. J Clin Epidemiol 1996;49:411-17
   PubMed Web of Science ®Google Scholar
• Dunstan D, Zimmet P, Welborn T, et al.; on behalf of the AusDiab Steering Committee. Diabetes & associated disorders in Australia 2000 – the accelerating epidemic. The Australian Diabetes, Ob, 2001
   Google Scholar
• Palmer AJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(Suppl 1):S5-26
   PubMed Web of Science ®Google Scholar
• Bagust A, Hopkinson PK, Maier W, Currie CJ. An economic model of the long-term health care burden of type II diabetes. Diabetologia 2001;44:2140-55
   PubMed Web of Science ®Google Scholar
• Eddy DM, Schlessinger L. Archimedes: a trial-validated model of diabetes. Diabetes Care 2003;26:3093-101
   PubMed Web of Science ®Google Scholar
• Mount Hood 4 Modeling Group. Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care 2007;30:1638-46
   PubMed Web of Science ®Google Scholar
• Palmer AJ, et al. Outline of a diabetes disease management model: principles and applications. Diabetes Res. Clin. Pract. 50(Suppl) 2000;3:S47-56
   Google Scholar
• Chen J, Alemao E, Yin D, Cook J. Development of a diabetes treatment simulation model: with application to assessing alternative treatment intensification strategies on survival and diabetes-related complications. Diabetes Obes Metab 2008;10(Suppl 1):33-42
   PubMed Web of Science ®Google Scholar
• Mueller E, et al. Development and validation of the Economic Assessment of Glycemic Control and Long-Term Effects of diabetes (EAGLE) model. Diabetes Technol Ther 2006;8:219-36
   PubMed Web of Science ®Google Scholar
• Brändle M, Azoulay M, Greiner RA. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland. Int J Clin Pharmacol Ther 2007;45:203-20
   PubMed Web of Science ®Google Scholar
• Hayes AJ, Leal J, Gray AM, et al. UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia 2013;56:1925-33
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Type 2 diabetes in adults. 2015. Available at: http://www.nice.org.uk/guidance/conditions-and-diseases/diabetes-and-other-endocrinal–nutritional-and-metabolic-conditions/diabetes
   Google Scholar